Eirini Pectasides
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eirini Pectasides has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Esther A. Peterson
Departments of Developmental & Molecular Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
1 shared publication - Joseph A. Sparano
Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute
1 shared publication - Lisa Wiechmann
Departments of Surgery, Albert Einstein College of Medicine, Bronx, NY 10461, USA
1 shared publication - Paraic A. Kenny
Departments of Developmental & Molecular Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
1 shared publication - Shabana Shabbeer
Departments of Developmental & Molecular Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
1 shared publication
Latest Publications
- Open Access
- 1 March 2018
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 10 (3) , 1276-1279
Immune checkpoint blockade in esophageal squamous cell carcinoma: is it ready for prime time?
Immune checkpoint blockade in esophageal squamous cell carcinoma: is it ready for prime time?
- 1 March 2018
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 10 (3) , 1276-1279
Open AccessImmune checkpoint blockade in esophageal squamous cell carcinoma: is it ready for prime time?
Immune checkpoint blockade in esophageal squamous cell carcinoma: is it ready for prime time?
- Open Access
- 8 September 2013
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 2 (1) , 25
Evaluation of serum Amphiregulin levels in breast cancer patients and cancer-free controls
Background: Expression of the Epidermal Growth Factor Receptor ligand, Amphiregulin, has been associated with estrogen receptor positive breast cancer. As Amphiregulin is proteolytically released from the surface of breast cancer cells, we investigated the levels of Amphiregulin in the serum of breast cancer patients and cancer-free women to evaluate its potential utility as a breast cancer biomarker. Findings: Serum Amphiregulin levels were quantified by ELISA from 125 cancer-free women and 114 breast cancer patients. No significant association between serum Amphiregulin levels and breast cancer status was detected at two cut-points evaluated. Conclusions: Measurement of serum Amphiregulin levels lacks the necessary sensitivity and specificity for breast cancer screening in the general population.
- 8 September 2013
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 2 (1) , 25
Open AccessEvaluation of serum Amphiregulin levels in breast cancer patients and cancer-free controls
Background: Expression of the Epidermal Growth Factor Receptor ligand, Amphiregulin, has been associated with estrogen receptor positive breast cancer. As Amphiregulin is proteolytically released from the surface of breast cancer cells, we investigated the levels of Amphiregulin in the serum of breast cancer patients and cancer-free women to evaluate its potential utility as a breast cancer biomarker. Findings: Serum Amphiregulin levels were quantified by ELISA from 125 cancer-free women and 114 breast cancer patients. No significant association between serum Amphiregulin levels and breast cancer status was detected at two cut-points evaluated. Conclusions: Measurement of serum Amphiregulin levels lacks the necessary sensitivity and specificity for breast cancer screening in the general population.